Certara to Integrate NVIDIA BioNeMo AI Toolkit, Boosting Drug Discovery Capabilities
CERT sits 61% above its 52-week low of $4.45.
Summary
Certara is partnering with NVIDIA to integrate the BioNeMo Agent Toolkit into its AI platform, aiming to accelerate drug discovery and development. This collaboration unifies Certara's biosimulation software, data, and scientific expertise with NVIDIA's advanced AI-driven agents. The move is expected to enhance the speed, scale, and reproducibility of insight generation for life sciences clients, strengthening Certara's competitive position in model-informed drug development.
At the time of this announcement, CERT was trading at $7.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $4.45 to $13.88. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.